摘要
血小板长期以来一直被认为是止血和血栓形成的关键参与者;然而,越来越多的证据表明,它们也与癌症有关。临床前和临床研究表明,血小板可以通过血小板和癌细胞之间的各种串扰来促进肿瘤发生和转移。血小板在肿瘤发生的各个阶段,包括肿瘤生长、肿瘤细胞外渗和转移中都发挥着积极的作用。此外,癌症患者的血小板增多与患者不良生存率相关。由于大量的微粒和外泌体,血小板还能够很好地协调局部和远处的肿瘤-宿主之间的相互作用。因此,以血小板为靶点的抗肿瘤药物具有很大的开发与应用前景。以下将对靶向血小板的抗肿瘤药物研究进展进行综述。
Platelets have long been recognized as key players in hemostasis and thrombosis;however,there is growing evidence that they are also involved in cancer.Preclinical and clinical studies have shown that platelets can promote tumorigenesis and metastasis through various crosstalks between platelets and cancer cells.Platelets play an active role in all stages of tumorigenesis,including tumor growth,tumor cell extravasation,and metastasis.In addition,thrombocytosis in cancer patients is associated with poor patient survival.Platelets are also well-placed to coordinate local and distant tumor-host interactions due to the abundance of microparticles and exosomes.Therefore,antitumor drugs targeting platelets have great development and application prospects.The following will review the research progress of anti-tumor drugs targeting platelets.
作者
周玥珂
钱程
唐彧
韦忠红
陆茵
王爱云
ZHOU Yue-ke;QIAN Cheng;TANG Yu;WEI Zhong-hong;LU Yin;WANG Ai-yun(Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica,School of Pharmacy,Nanjing 210023,China;Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine Prevention and Treatment of Tumor,Nanjing University of Chinese Medicine,Nanjing 210023,China)
出处
《中国药理学通报》
CAS
CSCD
北大核心
2024年第1期20-25,共6页
Chinese Pharmacological Bulletin
基金
国家自然科学基金资助项目(No 81573859)
全国中医药创新骨干人才培训项目(国中医药人教函【2019】128号文)
江苏省研究生科研创新计划(SJCX22_0791)。
